George Clinical and the China Anti-Cancer Association Australia launch inaugural research seminar

26 SEPTEMBER, 2018 – (SYDNEY) In recognition of the largest non-English speaking ethnic groups in Australia, George Clinical, a leading Asia Pacific CRO, and the China Anti-Cancer Association Australia (CACA) have joined together to launch the inaugural CACA research seminar entitled: Cancer incidence, palliative care among Chinese migrants to Australia. The event, which will be […]

Read More

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO.

9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]

Read More

There has never been a better time to consider China as part of your development strategy!

In another encouraging step towards making China a leading destination for clinical drug trials, some critical developments were announced at The Executive Meeting of the State Council on the 12th April 2018. From 1 May 2018, the import tariff of all common drugs including anticancer drugs, alkaloids with anticancer effects and the imported Chinese patent […]

Read More

George Clinical Promotes Matthew Reabold, Sr., to Head of Business Development, USA

George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. George Clinical, headquartered in Sydney, Australia, operates in fifteen countries around the world and has major operational hubs in the USA, East Asia, China, and India. Matthew, who is USA based, will […]

Read More

Significant changes ahead for drug development in China?

Significant changes are ahead for clinical research in China. The Public Consultation Notice for Policies to Encourage Innovation and Reform in Regulation of Drug and Medical Device Clinical Testing was released by the CFDA on 11 May, 2017. These proposed changes herald an exciting new era for drug and device development. If implemented in full, […]

Read More

George Clinical, leading Asia-Pacific CRO, expands into US with acquisition of a specialised oncology CRO Division

Sydney, Australia (May 2, 2017) – George Clinical, a leading full-service CRO in the Asia-Pacific region and Vector Oncology, a Memphis-based leader in oncology research and data analytics, formally announced today that George Clinical has acquired Vector Oncology’s CRO Division. Effective immediately, the transaction has the dual purpose of strengthening the ability of George Clinical […]

Read More

Hong Kong Wholesale Dealer Licence

George Clinical is pleased to announce the receipt of their Hong Kong Wholesale Dealer licence issued by the Department of Health on the 3rd April. This licence represents a significant step forward in George Clinical’s operations in Hong Kong, allowing them to apply for a Certificate of Clinical Trial on behalf of the sponsor and […]

Read More

Taiwan: The Clinical Trials Gateway to China?

Taiwan sits, along with its smaller counterparts, Singapore and Hong Kong, as one of the gateway countries to running a clinical trial in China. Although Hong Kong’s regulatory ties are more formalized with China, than Taiwan, Taiwan has the right environment and population to make the possibility of greater regulatory cohesion with its giant neighbour, […]

Read More

South Korea: A Top Clinical Trial Destination

Clinical trial sponsors and CROs don’t need to imagine South Korea as a country of limitless potential, they know it is. South Korea is a clinical trial destination with world-class medical infrastructure, a highly-educated, relatively wealthy and healthy population. Their investigators are, on the whole, actively engaged in clinical trials and keen to play their […]

Read More

International Women’s Day

As the world stops to celebrate and reflect on International Women’s Day on the 8th of March, George Clinical is proud to play their part in #beboldforchange. Traditionally the commercial research sector has a larger proportion of female practitioners than men. Indeed, at George Clinical, the proportion female to men at 158:73 and with a […]

Read More

Twitter Facebook LinkedIn